Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in

Clinical Trial Summary

Surgical resection of the primary tumour and treatment of the metastatic site in oligometastatic stage IV metastatic gastric adenocarcinoma enhances survival and improves quality of life with acceptable postoperative morbidity and mortality in a selected group of operable patients with only one metastatic site that does not progress under chemotherapy.

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05977998` - A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology	Phase 2
Recruiting	`NCT05059444` - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Not yet recruiting	`NCT04931420` - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels	Phase 2
Recruiting	`NCT03257163` - Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer	Phase 2
Completed	`NCT02128243` - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer	Phase 2
Completed	`NCT01178944` - Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer	Phase 2
Terminated	`NCT00209079` - Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma	Phase 2
Terminated	`NCT02862535` - Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 1
Active, not recruiting	`NCT05008783` - A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma	Phase 3
Recruiting	`NCT04430738` - Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers	Phase 1/Phase 2
Recruiting	`NCT04114136` - Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies	Phase 2
Completed	`NCT03196232` - Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer	Phase 2
Recruiting	`NCT04047953` - Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma	N/A
Completed	`NCT02891447` - Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer	Phase 2
Completed	`NCT02864381` - Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2
Terminated	`NCT04032704` - A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors	Phase 2
Terminated	`NCT04604132` - Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma	Phase 1/Phase 2
Completed	`NCT02830594` - Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer	Phase 2
Recruiting	`NCT06038578` - A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer	Phase 2
Terminated	`NCT04099277` - A Study of LY3435151 in Participants With Solid Tumors	Phase 1

NCT number	NCT03042169
Study type	Interventional
Source	University Hospital, Lille
Contact	Guillaume Piessen, MD,PhD
Phone	0320445962
Email	guillaume.piessen@chru-lille.fr
Status	Recruiting
Phase	Phase 3
Start date	August 25, 2021
Completion date	February 2023

Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer — SURGIGAST

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms